AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01664754
Drug: pemetrexed disodium
RxNorm normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT01664754
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02765399
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03358030
Drug: ISIS 416858
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT04373421
Drug: Chlorhexidine Gluconate 0.12 % Mouthwash + benzydamine hydrochloride
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After anesthesia, the horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under abundant irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with sterile 0.9% saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures. The patients were postoperatively prescribed paracetamol (Parol® 500 mg, Atabay Chemical Industry, Istanbul, Turkey) to use when required with a maximum of 4 doses per day. Patients were instructed to maintain a soft diet, and refrain from mouth washing, brushing and flossing during the first 24 hour. They were also instructed to rinse their mouth with 15 ml of mouthwash for 30 seconds, 3 times a day, and continue until the 7th postoperative day.
Trial: NCT02949492
Drug: IL-2 (interleukin 2)
RxNorm normalized name: Ile
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
Trial: NCT03829111
Drug: Clostridium butyricum CBM 588 Probiotic Strain
RxNorm normalized name: Clostridium tetani
DrugBank: Clostridium tetani (DB09876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00716274
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
Trial: NCT01529229
Drug: Dexchlorpheniramine + Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Trial: NCT01529229
Drug: Desloratadine + Prednisolone
RxNorm normalized name: Desloratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
Trial: NCT01932788
Drug: Vitamin D3 4000 IU in gummy form
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
Trial: NCT01977378
Drug: Sustained-Release Desvenlafaxine Hydrochloride
RxNorm normalized name: desvenlafaxine Extended Release Oral Tablet
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01977378
Drug: Sustained-Release Venlafaxine Hydrochloride
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04042805
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Trial: NCT00185887
Drug: Terbutaline
RxNorm normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
Trial: NCT01900886
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment as usual clinical practice
Trial: NCT02579811
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
Trial: NCT04264039
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/m\^2 per day for 6 days
Trial: NCT04264039
Drug: Cytoxan
RxNorm normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
Trial: NCT04264039
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
Trial: NCT02806414
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02382588
Drug: gancyclovir gel
RxNorm normalized name: Gancyclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
Trial: NCT02382588
Drug: Hypromellose gel
RxNorm normalized name: Hypromellose
DrugBank: Hypromellose (DB11075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
Trial: NCT02350218
Drug: Eglandin
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
Trial: NCT02394158
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04624178
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rucaparib at 600 mg, orally, twice daily, continuously for 28 days.
Trial: NCT04624178
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 480mg intravenously on day 1 of every four-week cycle.
Trial: NCT00708357
Drug: NG-monomethyl-L-arginine
RxNorm normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous administration, bolus over 5 minutes, dosage 6mg/kg
Trial: NCT02109614
Drug: Extended release Niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
Trial: NCT02268383
Drug: Luspatercept
RxNorm normalized name: Luspatercept
DrugBank: Luspatercept (DB12281)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Luspatercept 1.0 mg/kg once every 3 weeks by subcutaneous injection.
Trial: NCT01384396
Drug: KW-3357
RxNorm normalized name: Antithrombin (human variant kw-3357)
DrugBank: Antithrombin Alfa (DB11166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion once a day
Trial: NCT02723084
Drug: sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT02723084
Drug: ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule
Trial: NCT01911468
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01911468
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01911468
Drug: metformin and liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01101451
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02470702
Drug: Oritavancin
RxNorm normalized name: Oritavancin
DrugBank: Oritavancin (DB04911)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02914938
Drug: ME-401
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
DrugBank: Lactobacillus fermentum (DB16542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg
Trial: NCT02914938
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion 375 mg/m2
Trial: NCT02914938
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 80 and 160 mg bid
Trial: NCT00201279
Drug: 13-cis Retino Acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002593
Drug: levamisole hydrochloride
RxNorm normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as described in arm description
Trial: NCT03310944
Drug: sotagliflozin (SAR439954)
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablets~Route of administration: oral
Trial: NCT03382912
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab Alone
Trial: NCT04443088
Drug: INV-1120
RxNorm normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
Trial: NCT03552016
Drug: Oral Riboflavin
RxNorm normalized name: riboflavin Oral Capsule
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
Trial: NCT03626714
Drug: Sustained Release Injectable Tacrolimus
RxNorm normalized name: tacrolimus Injection
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
Trial: NCT00752414
Drug: MP-376 (Levofloxacin solution for Inhalation)
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily for 5 days
Trial: NCT00654173
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03168139
Drug: Olaptesed pegol - Monotherapy
RxNorm normalized name: Certolizumab Pegol
DrugBank: Olaptesed Pegol (DB11707)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks
Trial: NCT03168139
Drug: Olaptesed pegol + Pembrolizumab - Combination Therapy
RxNorm normalized name: Olaptesed Pegol
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total
Trial: NCT02199041
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by intravenous infusion as part of the preparative regimen.
Trial: NCT02199041
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by intravenous infusion as part of the preparative regimen.
Trial: NCT02199041
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by intravenous infusion as part of the preparative regimen.
Trial: NCT02199041
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
Trial: NCT02199041
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
Trial: NCT02199041
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
Trial: NCT02199041
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
Trial: NCT02065232
Drug: Tilmanocept
RxNorm normalized name: tilmanocept
DrugBank: Tilmanocept (DB15373)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02065232
Drug: Sulfur Colloid
RxNorm normalized name: Sulfur Colloid
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03041935
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT03041935
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT00225251
Drug: bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant medication
Trial: NCT03787251
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
Trial: NCT00842686
Drug: bevacizumab, capecitabine
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
Trial: NCT00156533
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of Zolpidem
Trial: NCT00156533
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04322253
Drug: Neladenoson bialanate (BAY 1067197)
RxNorm normalized name: Regadenoson
DrugBank: Neladenoson bialanate (DB13138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg as a single IR tablet dose. Active metabolite: BAY 84-3174
Trial: NCT01714154
Drug: danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg orally every 12 hours
Trial: NCT01714154
Drug: ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg orally every 12 hours
Trial: NCT01714154
Drug: setrobuvir
RxNorm normalized name: Setrobuvir
DrugBank: Setrobuvir (DB12051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg orally every 12 hours
Trial: NCT00249444
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine
Trial: NCT01499667
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fingolimod 0.5 mg capsules for oral administration once daily
Trial: NCT02673489
Drug: DCV
RxNorm normalized name: DCV
DrugBank: AV-COVID-19 (DB15802)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02673489
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01918904
Drug: Sodium thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
Trial: NCT03041935
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT03041935
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT03041935
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See arm description
Trial: NCT03041935
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT00947128
Drug: Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00947128
Drug: Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
RxNorm normalized name: ondansetron Oral Tablet [Zofran]
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01897532
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00087217
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00243789
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, \<30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day.
Trial: NCT01870739
Drug: sacubitril/valsartan (LCZ696)
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg tablets
Trial: NCT00087217
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00002429
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002429
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002429
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002429
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01870739
Drug: olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01870739
Drug: Amlodipine (Optional)
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
Trial: NCT03538743
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 15 mg twice daily, 28 days
Trial: NCT03538743
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 50 mg twice daily, 28 days
Trial: NCT03538743
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 150 mg twice daily, 28 days
Trial: NCT03538743
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 300 mg twice daily, 28 days
Trial: NCT03538743
Drug: PF-06882961
RxNorm normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, dose TBD, twice daily, Cohort 5, 28 days
Trial: NCT00122889
Drug: Garlic powder with high allicin content
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00122889
Drug: Garlic powder with low allicin content
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no